KRAS

[Critical Reviews in Oncology/Hematology] Pancreatic cancer (PC) remains an incurable disease with few treatment options. Recently, promising targets have been identified and novel therapeutic drugs are currently under development in KRAS wild-type PC.

[Cancer Cell International] Researchers analyzed the expression of BCL10-, cell cycle-, and NF-κB- related signaling molecules, and the DNA-binding activity of NF-κB in three pancreatic ductal adenocarcinoma cell lines using BCL10 short hairpin RNA.

[Nature Communications] Scientists showed that the deubiquitinase USP12 was commonly downregulated in the KrasG12D-driven mouse lung tumour and human non-small cell lung cancer owing to the activation of AKT-mTOR signalling.

[Cancer Discovery] The authors found that SHP2 inhibitor treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non-small cell lung cancer.

[Nature Communications] Scientists investigated the oncogene-specific dependencies conferred by the lung cancer oncogene, RIT1. Genome-wide CRISPR screening in KRAS, EGFR, and RIT1-mutant isogenic lung cancer cells identifies shared and unique vulnerabilities of each oncogene..

[eFFECTOR Therapeutics, Inc.] eFFECTOR Therapeutics, Inc. announced the initiation of dosing in the Phase IIa expansion portion of an ongoing Phase I/II trial of zotatifin in solid tumors. eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer.